LeMaitre Vascular, Inc.

NasdaqGM:LMAT Stock Report

Market Cap: US$2.0b

LeMaitre Vascular Past Earnings Performance

Past criteria checks 5/6

LeMaitre Vascular has been growing earnings at an average annual rate of 13.3%, while the Medical Equipment industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 12.5% per year. LeMaitre Vascular's return on equity is 12.5%, and it has net margins of 19.4%.

Key information

13.3%

Earnings growth rate

10.4%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate12.5%
Return on equity12.5%
Net Margin19.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) 26% Price Boost Is Out Of Tune With Earnings

Nov 24
LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) 26% Price Boost Is Out Of Tune With Earnings

LeMaitre Vascular: The Market Is Catching On To This Dividend Growth Story

Nov 03

LeMaitre Vascular, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Nov 02
LeMaitre Vascular, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Potentially Undervalued?

Oct 08
Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Potentially Undervalued?

Investors Met With Slowing Returns on Capital At LeMaitre Vascular (NASDAQ:LMAT)

Sep 17
Investors Met With Slowing Returns on Capital At LeMaitre Vascular (NASDAQ:LMAT)

LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Price In Tune With Earnings

Sep 04
LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Price In Tune With Earnings

If EPS Growth Is Important To You, LeMaitre Vascular (NASDAQ:LMAT) Presents An Opportunity

Aug 22
If EPS Growth Is Important To You, LeMaitre Vascular (NASDAQ:LMAT) Presents An Opportunity

LeMaitre Vascular: A Small Cap With Best-In-Industry Growth

Jul 23

Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Worth US$85.0 Based On Its Intrinsic Value?

Jul 12
Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Worth US$85.0 Based On Its Intrinsic Value?

Is There Now An Opportunity In LeMaitre Vascular, Inc. (NASDAQ:LMAT)?

Jun 18
Is There Now An Opportunity In LeMaitre Vascular, Inc. (NASDAQ:LMAT)?

Return Trends At LeMaitre Vascular (NASDAQ:LMAT) Aren't Appealing

Jun 05
Return Trends At LeMaitre Vascular (NASDAQ:LMAT) Aren't Appealing

LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Popularity With Investors Is Clear

May 02
LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Popularity With Investors Is Clear

Is Now The Time To Put LeMaitre Vascular (NASDAQ:LMAT) On Your Watchlist?

Apr 04
Is Now The Time To Put LeMaitre Vascular (NASDAQ:LMAT) On Your Watchlist?

Calculating The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Feb 29
Calculating The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

What Does LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Share Price Indicate?

Jan 19
What Does LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Share Price Indicate?

Returns On Capital At LeMaitre Vascular (NASDAQ:LMAT) Paint A Concerning Picture

Oct 27
Returns On Capital At LeMaitre Vascular (NASDAQ:LMAT) Paint A Concerning Picture

Is It Too Late To Consider Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT)?

Oct 11
Is It Too Late To Consider Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT)?

Does LeMaitre Vascular (NASDAQ:LMAT) Deserve A Spot On Your Watchlist?

Aug 30
Does LeMaitre Vascular (NASDAQ:LMAT) Deserve A Spot On Your Watchlist?

The Returns On Capital At LeMaitre Vascular (NASDAQ:LMAT) Don't Inspire Confidence

Jul 06
The Returns On Capital At LeMaitre Vascular (NASDAQ:LMAT) Don't Inspire Confidence

Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Worth US$62.3 Based On Its Intrinsic Value?

May 20
Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Worth US$62.3 Based On Its Intrinsic Value?

Should You Think About Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT) Now?

Mar 12
Should You Think About Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT) Now?

Should You Think About Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT) Now?

Oct 23
Should You Think About Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT) Now?

Calculating The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Oct 05
Calculating The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

LeMaitre Vascular (NASDAQ:LMAT) Could Be Struggling To Allocate Capital

Sep 13
LeMaitre Vascular (NASDAQ:LMAT) Could Be Struggling To Allocate Capital

LeMaitre Vascular: Reiterate Buy Thesis Following Strong Q2 Numbers

Sep 08

LeMaitre Vascular goes ex dividend tomorrow

Aug 23

Revenue & Expenses Breakdown

How LeMaitre Vascular makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:LMAT Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24213418016
30 Jun 24206387717
31 Mar 24200347517
31 Dec 23193307317
30 Sep 23186277016
30 Jun 23177256815
31 Mar 23169216514
31 Dec 22162216213
30 Sep 22160216013
30 Jun 22160225813
31 Mar 22158275512
31 Dec 21154275312
30 Sep 21152285111
30 Jun 21151294910
31 Mar 21135244610
31 Dec 20129214610
30 Sep 20122194710
30 Jun 20115164810
31 Mar 20119185010
31 Dec 1911718499
30 Sep 1911519489
30 Jun 1911118479
31 Mar 1910823469
31 Dec 1810623458
30 Sep 1810321447
30 Jun 1810422447
31 Mar 1810318437
31 Dec 1710117437
30 Sep 179815437
30 Jun 179614436
31 Mar 179312426
31 Dec 168911406
30 Sep 168611396
30 Jun 16829386
31 Mar 16799376
31 Dec 15788375
30 Sep 15767365
30 Jun 15746365
31 Mar 15735364
31 Dec 14704365
30 Sep 14703365
30 Jun 14673365
31 Mar 14652365
31 Dec 13643355

Quality Earnings: LMAT has high quality earnings.

Growing Profit Margin: LMAT's current net profit margins (19.4%) are higher than last year (14.7%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: LMAT's earnings have grown by 13.3% per year over the past 5 years.

Accelerating Growth: LMAT's earnings growth over the past year (51.5%) exceeds its 5-year average (13.3% per year).

Earnings vs Industry: LMAT earnings growth over the past year (51.5%) exceeded the Medical Equipment industry 12.9%.


Return on Equity

High ROE: LMAT's Return on Equity (12.5%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 15:22
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

LeMaitre Vascular, Inc. is covered by 22 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael PetuskyBarrington Research Associates, Inc.
Raymond MyersBenchmark Company
Jan WaldBenchmark Company